Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16355197 | 0.87 | KDM1A (0.49) | ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL12403796 | 0.84 | ALDH1A1 (0.57) | ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL15432476 | 0.84 | KCNH2 (0.41) | — | |
| SCHEMBL3485097 | 0.81 | HTR7 (0.54) | SMN1; SMN2 | |
| SCHEMBL13117452 | 0.80 | RIPK1 (0.41) | ALDH1A1 | |
| SCHEMBL29196369 | 0.79 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10208721 | 0.79 | MEN1 (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL16355200 | 0.78 | KDM1A (0.48) | ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL15432479 | 0.78 | PTPN7 (0.45) | ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL16355198 | 0.77 | MMP13 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9301951-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2015-06-18 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164876-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | ALDH1A1 2892/4885CYP2D6 738/4885SMN1; SMN2 4868/4885 |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | ALDH1A1 2892/4885CYP2D6 738/4885SMN1; SMN2 4868/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | ALDH1A1 226/4885CYP2D6 883/4885SMN1; SMN2 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.